Celcuity Inc.
Close on Oct 19, 2026
- Market cap
- $3.13B
- P/E (TTM)
- –
- Dividend yield
- –
About Celcuity
Services-Medical Laboratories, SIC 8071
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies to treat various solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor targeting class I PI3K isoforms and mTOR complexes (mTORC1 and mTORC2) to achieve comprehensive inhibition of the PAM signaling pathway. The company is evaluating this candidate in clinical studies primarily for patients with advanced breast cancer and metastatic castration-resistant prostate cancer who have experienced disease progression on prior standard therapies.
Celcuity conducts clinical research across a global footprint, including expected participation from roughly 200 clinical study sites spanning North America, Europe, and the Asia-Pacific region. Incorporated in Delaware, the company maintains its principal executive offices and headquarters in Minneapolis, Minnesota.
Summary of the business section of Celcuity's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Celcuity Inc.
- Headquarters
- Minneapolis, MN
- Address
- 16305 36th Avenue N, Suite 100 55446
- Phone
- (763) 392-0767
- Website
- celcuity.com
- Employees
- 155, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Boulay LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- CELC
- Exchange
- Nasdaq
- IPO date
- Sep 20, 2017
- Shares outstanding
- 49M, Aug 5, 2026
- Public float
- $457.49M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1603454
- CUSIP
- 15102K100
- ISIN
- US15102K1007
- LEI
- 25490070W7UU7W2SEY87
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lance G. Laing | Chief Science Officer, Director | 1,271,000 |
| Brian F. Sullivan | Chief Executive Officer, Director | 3,200,983 |
| Vicky Hahne | Chief Financial Officer | 37,808 |
| Richard E. Buller | Director | 9,319 |
| Polly A. Murphy | Director | 6,530 |
| Charles R. Romp | Director | 1,745 |
| Richard Nigon | Director | 100,865 |
| David Dalvey | Director | 66,530 |
| Leo Furcht | Director | 12,530 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian F. Sullivan | $16.37M | $63.04M | $3.80M | $712 | – |
| FY2024 Brian F. Sullivan | $6.59M | $5.20M | $1.53M | $93 | – |
| FY2023 Brian F. Sullivan | $1.74M | $2.46M | $1.19M | $104 | – |
| FY2022 Brian F. Sullivan | $1.81M | $2.49M | $599.44K | $106 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 155 full-time employees, most of which were engaged in research and development activities, though hiring”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 20, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 15, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 15, 2017 | Name change | Name changed from Celcuity LLC to Celcuity Inc. |